The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Open accessAbstract
BACKGROUND: Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in critically ill patients. Colistin often remains the only therapeutic option. Addition of rifampicin to colistin may be synergistic in vitro. In this study, we assessed whether the combination of colistin and rifampicin reduced the mortality of XDR A. baumannii infections compared to colistin alone. METHODS: This multicenter, parallel, randomized, open-label clinical trial enrolled 210 patients with life-threatening infections due to XDR A. baumannii from intensive care units of 5 tertiary care hospitals. Patients were randomly allocated (1:1) to either colistin alone, 2 MU every 8 hours intravenously, or colistin (as above), plus rifampicin 600 mg every 12 hours intravenously. The primary end point was overall 30-day mortality. Secondary end points were infection-related death, microbiologic eradication, and hospitalization length. RESULTS: Death within 30 days from randomization occurred in 90 (43%) subjects, without difference between treatment arms (P = .95). This was confirmed by multivariable analysis (odds ratio, 0.88 [95% confidence interval, .46-1.69], P = .71). A significant increase of microbiologic eradication rate was observed in the colistin plus rifampicin arm (P = .034). No difference was observed for infection-related death and length of hospitalization. CONCLUSIONS: In serious XDR A. baumannii infections, 30-day mortality is not reduced by addition of rifampicin to colistin. These results indicate that, at present, rifampicin should not be routinely combined with colistin in clinical practice. The increased rate of A. baumannii eradication with combination treatment could still imply a clinical benefit. CLINICAL TRIALS REGISTRATION: NCT01577862.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Guidelines for the management of intravascular catheter-related infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320001 · Cited by 1,449
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Munoz-Price, L. S., & Weinstein, R. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra070741 · Cited by 772
[Antibiogram Committee of the French Society for Microbiology. Official Statement 1999].
Soussy, C. (1999) · PubMed · Cited by 677
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Global spread of carbapenem-resistant Acinetobacter baumannii
Higgins, P. G., Dammhayn, C., Hackel, M., & Seifert, H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp428 · Cited by 607
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections
Solomkin, J. S., Mazuski, J. E., Baron, E. J., Sawyer, R. G., Nathens, A. B., DiPiro, J. T., Buchman, T., Dellinger, E. P., Jernigan, J., Gorbach, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378702 · Cited by 515
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization
Sunenshine, R. H., Wright, M.-O., Maragakis, L. L., Harris, A. D., Song, X., Hebden, J., Cosgrove, S. E., Anderson, A., Carnell, J., Jernigan, D. B., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060716 · Cited by 411
Treatment of Acinetobacter Infections
Fishbain, J., & Peleg, A. Y. (2010) · Clinical Infectious Diseases · doi:10.1086/653120 · Cited by 358
Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
Falagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Falagas, M. E., Bliziotis, I. A., & Siempos, I. I. (2006) · Critical Care · doi:10.1186/cc4869 · Cited by 272
Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M. L., Coppolecchia, S., Miragliotta, G., Bruno, F., & Brienza, N. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis286 · Cited by 247
Petrosillo, N., Ioannidou, E., & Falagas, M. E. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02061.x · Cited by 213
Self-citationGuidelines for the Management of Intravascular Catheter-Related Infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Infection Control & Hospital Epidemiology · doi:10.1086/501893 · Cited by 204
Markou, N., Markantonis, S. L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., Rafailidis, P., Apostolakos, H., & Baltopoulos, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.01.015 · Cited by 191
Reina, R., Estenssoro, E., Sáenz, G., Canales, H. S., Gonzalvo, R., Vidal, G., Martins, G., Das Neves, A., Santander, O., & Ramos, C. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2691-4 · Cited by 186
Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital
DeRyke, C. A., Crawford, A. J., Uddin, N., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01707-09 · Cited by 178
Durante‐Mangoni, E., & Zarrilli, R. (2011) · Future Microbiology · doi:10.2217/fmb.11.23 · Cited by 173
Self-citationMotaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., Belabbes, H., & Benbachir, M. (2006) · Journal of Infection · doi:10.1016/j.jinf.2005.11.019 · Cited by 165
Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections
Bassetti, M., Repetto, E., Righi, E., Boni, S., Diverio, M., Molinari, M. P., Mussap, M., Artioli, S., Ansaldi, F., Durando, P., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm509 · Cited by 163
Self-citationPachón-Ibáñez, M. E., Docobo-Pérez, F., López-Rojas, R., Domínguez-Herrera, J., Me, J.-M., García-Curiel, A., Pichardo, C., Jiménez, L., & Pachón, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00367-09 · Cited by 114
Colistin pharmacokinetics: the fog is lifting
Couet, W. R., Grégoire, N., Marchand, S., & Mimoz, O. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03667.x · Cited by 111
Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of Gram-negative bacteria
Savage, P. B. (2001) · Annals of Medicine · doi:10.3109/07853890109002073 · Cited by 96
Pantopoulou, A., Giamarellos‐Bourboulis, E. J., Raftogannis, M., Τσαγανός, Θ., Dontas, I. A., Koutoukas, P., Baziaka, F., Giamarellou, H., & Perrea, D. N. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.09.009 · Cited by 77
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-16 · Cited by 1,170
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Self-citation
Metadata
- Authors
- Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., Mocavero, P., Corcione, A., Viscoli, C., Zarrilli, R., Gallo, C., & Utili, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-24
- Volume
- 57
- Issue
- 3
- Pages
- 349-358
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134377638
- Cited by
- 405
- References
- 34
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.